Ildong Holdings Co., Ltd. (KRX:000230)
10,850
-850 (-7.26%)
At close: Oct 1, 2025
Ildong Holdings Revenue
Ildong Holdings had revenue of 148.84B KRW in the quarter ending June 30, 2025, a decrease of -5.64%. This brings the company's revenue in the last twelve months to 635.42B, up 0.30% year-over-year. In the year 2024, Ildong Holdings had annual revenue of 657.57B with 2.99% growth.
Revenue (ttm)
635.42B
Revenue Growth
+0.30%
P/S Ratio
0.18
Revenue / Employee
8.83B
Employees
72
Market Cap
116.31B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 657.57B | 19.12B | 2.99% |
Dec 31, 2023 | 638.45B | -37.09B | -5.49% |
Dec 31, 2022 | 675.54B | 83.17B | 14.04% |
Dec 31, 2021 | 592.37B | -4.09B | -0.69% |
Dec 31, 2020 | 596.47B | 304.25B | 104.12% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Samsung Biologics | 5,031.69B |
Celltrion | 3,748.95B |
ALTEOGEN | 158.06B |
Yuhan | 2,165.44B |
SK Biopharmaceuticals | 620.28B |
Peptron | 5.18B |
PharmaResearch | 449.81B |
LigaChem Biosciences | 148.28B |